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Successful Treatment of Cryptococcal Meningitis 
with Voriconazole in a Kidney Transplant 
Recipient 
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Switzerland, 2Department of Transplantation 
Immunology and Nephrology, University Hospital 
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Background: Current treatment for cryptococ- 
cal (C) meningitis consists in an initial course of 
amphotericin B (AMPHO B) combined with Flucy- 
tosine (5-FC) for two weeks, followed by an oral 
suppressive therapy with Fluconazole (FLU). 
Objectives: We report the case of a kidney- 
transplant recipient successfully treated with 
Voriconazole (VOR) for C meningitis. 
Case: Four years after kidney transplantation a 
42-y-old woman was admitted with a 3 month his- 
tory of headache, and a 3 week history of nuchal 
rigidity, double vision, memory loss and fever. 
Immunosuppression consisted of sirolimus/aza- 
thioprine, changed to sirolimus/prednisone when 
C meningitis was diagnosed. Additionally, re- 
current episodes of hemolytic uremic syndrome 
were treated by plasmapheresis. White blood- 
cell count and CRP were normal, however CD4 
cells were reduced (196 cells/uL). Cerebrospinal 
Fluid (CSF) analysis showed an elevated intracra- 
nial pressure, elevated leukocytes (8/ul), pro- 
tein (1419 mg/l) and lactate (5.2 mmol/l) and a low 
glucose (<0.Smmol/l). India ink preparation and 
CSF culture were positive for C. neo[ormans. C 
antigen was 1:128 in serum and 1:512 in CSE MICs 
for AMPHO B were 0.5 mg/l, for FLU 8 mg/l and for 
VOR 0.064 mg/l. Blood cultures remained negative. 
Antifungal therapy with AMPHO B and 5-FC was 
initiated. Due to a rash, 5-FC was stopped after 
2 days. 10 days tater, CSF cultures remained pos- 
itive but clinical symptoms had resolved. AMPHO 
B was replaced by oral VOR because of the good 
penetration into CSF and the relative high MIC of 
FLU. CSF concentrations of VOR were between 0.75 
and 1.47mg/l. As cultures still were positive after 
5 weeks of therapy, VOR was replaced by liposo- 
male AMPHO B for another two weeks. Under this 
regimen CSF cultures still remained positive and 
serum C antigen rose from 1 : 128 to 1:1024. There- 
fore, therapy was changed back to VOR. Finally, 
ten weeks after antifungal therapy was started, 
cultures became negative and CSF antigen (1:64) 
as well as serum antigen (1:128) decreased. After 
18 months of treatment with VOR CSF and serum 
C antigen became undetectable. 
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Conclusions: We demonstrate successful treat- 
ment of C meningitis with oral VOR in an immuno- 
compromised patient. Of interest, an increase of 
C antigen was noted under monotherapy with li- 
posomale AMPHO B. Our patient showed a rapid 
clinical response to the antifungal treatment, white 
lacking in microbiological response as CSF cultures 
remained positive for ten weeks. 
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Background: Since CMV seronegative recipients of 
seropositive organ transplants are at high risk for 
CMV infection and disease they qualify for prophy- 
laxis using oral ganciclovir (GCV) or valGCV. Albeit 
rare, the occurrence of GCV-resistant CMV strains 
under treatment warrants the intravenous appli- 
cation of foscarnet as well as dose reductions of 
the immunosuppressive drugs use to prevent graft 
rejection. Paradoxically, the recovery of immune 
functions may result in a worsening of the clinical 
symptoms referred to as immune reconstitution 
syndrome (IRS). IRS is a well-known phenomenon i
HIV infected patients initiating HAART, but has only 
rarely been described in patients following solid 
organ transplantation. 
Objectives: We report a case of GCV-resistant pri- 
mary CMV infection early after liver transplanta- 
tion with severe bilateral CMV retinitis. 
Methods: CMV-antigenemia, CMV IgG/IgM titers 
and quantitative CMV PCR measurements were car- 
ried out following standard procedures. Peripheral 
blood mononudear cells (PBMC) were stimulated 
with viral protein (CMV lysat, pp72, pp65), and 
SEB as a positive control. CMV specific interferon 
gamma (IFNy) production of CD4+ and CD8+ T cells 
was measured by intracellular staining and flow cy- 
tometry analysis. Localization of the GCV-induced 
viral phosphotransferase (UL97) mutation was de- 
termined by real-time PCR. 
Results: A CMV seronegative recipient of a CMV 
seropositive liver transplant was treated with oral 
valGCV for the first three months posttransplant. 
